COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Georgina V. Long, Daniil L. Stroyakovsky, Helen Gogas, Eugeny Levchenko, Filippo de Braud, James M. G. Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob, Vanna Chiarion-Sileni, Celeste Lebbe, Mario Mandalà, Michael Millward, Douglas James DeMarini, Jhangir G Irani, Ngocdiep Le, Michelle Casey, Kiran Patel, Keith Flaherty
Institutions: Melanoma Institute Australia, Moscow City Oncology Hospital №62, National and Kapodistrian University of Athens, Institute of Oncology NN Petrov, Fondazione IRCCS Istituto Nazionale dei Tumori, Royal Marsden Hospital, Universitätsklinikum Tübingen, University of Tübingen, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, University Hospital Schleswig-Holstein, Hôpital Sainte-Marguerite, Istituto Oncologico Veneto, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, Sir Charles Gairdner Hospital, GlaxoSmithKline (United States), Harvard University, Massachusetts General Hospital
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2311386604